CO7111283A2 - Método de tratamiento de las dermatosis sensibles a los esteroides - Google Patents

Método de tratamiento de las dermatosis sensibles a los esteroides

Info

Publication number
CO7111283A2
CO7111283A2 CO14235154A CO14235154A CO7111283A2 CO 7111283 A2 CO7111283 A2 CO 7111283A2 CO 14235154 A CO14235154 A CO 14235154A CO 14235154 A CO14235154 A CO 14235154A CO 7111283 A2 CO7111283 A2 CO 7111283A2
Authority
CO
Colombia
Prior art keywords
chloro
methyl
treatment
sensitive dermatoses
pyrazol
Prior art date
Application number
CO14235154A
Other languages
English (en)
Spanish (es)
Inventor
Pankaj Agarwal
Vinod Kumar
Qing Xie
Original Assignee
Glaxosmithkline Ip No 2 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48143295&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO7111283(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Ip No 2 Ltd filed Critical Glaxosmithkline Ip No 2 Ltd
Publication of CO7111283A2 publication Critical patent/CO7111283A2/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/41551,2-Diazoles non condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CO14235154A 2012-04-24 2014-10-23 Método de tratamiento de las dermatosis sensibles a los esteroides CO7111283A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261637390P 2012-04-24 2012-04-24
US201361782565P 2013-03-14 2013-03-14

Publications (1)

Publication Number Publication Date
CO7111283A2 true CO7111283A2 (es) 2014-11-10

Family

ID=48143295

Family Applications (1)

Application Number Title Priority Date Filing Date
CO14235154A CO7111283A2 (es) 2012-04-24 2014-10-23 Método de tratamiento de las dermatosis sensibles a los esteroides

Country Status (26)

Country Link
US (2) US20150087683A1 (https=)
EP (1) EP2841053A1 (https=)
JP (1) JP2015514792A (https=)
KR (1) KR20150010943A (https=)
CN (1) CN104302275A (https=)
AR (1) AR090795A1 (https=)
AU (1) AU2013254849B2 (https=)
BR (1) BR112014026706A2 (https=)
CA (1) CA2873751A1 (https=)
CL (1) CL2014002861A1 (https=)
CO (1) CO7111283A2 (https=)
CR (1) CR20140491A (https=)
DO (1) DOP2014000238A (https=)
EA (1) EA201491914A1 (https=)
HK (1) HK1201726A1 (https=)
IL (1) IL235159A0 (https=)
MX (1) MX2014012904A (https=)
NZ (1) NZ628394A (https=)
PE (1) PE20142356A1 (https=)
PH (1) PH12014502400A1 (https=)
SG (1) SG11201406409VA (https=)
TW (1) TW201347758A (https=)
UA (1) UA113875C2 (https=)
UY (1) UY34762A (https=)
WO (1) WO2013160222A1 (https=)
ZA (1) ZA201407345B (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111821299A (zh) * 2019-04-16 2020-10-27 天津合美医药科技有限公司 噻吩衍生物用于治疗免疫球蛋白E(IgE)介导的疾病的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006002734A1 (en) * 2004-07-01 2006-01-12 Unilever N.V. Moisture barrier
ES2368930T3 (es) * 2004-09-06 2011-11-23 Bayer Pharma Aktiengesellschaft Pirazolopirimidinas como inhibidores de proteína cinasa b (akt).
AU2006235314B2 (en) * 2005-04-12 2011-01-20 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
UY30892A1 (es) * 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
CN102405047B (zh) * 2009-01-30 2014-07-09 葛兰素史密斯克莱有限责任公司 结晶型的n-{(1s)-2-氨基-1-[(3-氟苯基)甲基]乙基}-5-氯-4-(4-氯-1-甲基-1h-吡唑-5-基)-2-噻吩甲酰胺盐酸盐
JP2013507382A (ja) * 2009-10-08 2013-03-04 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 組合せ
WO2011146710A1 (en) * 2010-05-21 2011-11-24 Glaxosmithkline Llc Combination

Also Published As

Publication number Publication date
AR090795A1 (es) 2014-12-10
CL2014002861A1 (es) 2015-01-16
MX2014012904A (es) 2014-11-21
EA201491914A1 (ru) 2015-01-30
AU2013254849A1 (en) 2014-11-06
SG11201406409VA (en) 2014-11-27
US20160143885A1 (en) 2016-05-26
TW201347758A (zh) 2013-12-01
CN104302275A (zh) 2015-01-21
CR20140491A (es) 2014-12-22
ZA201407345B (en) 2015-11-25
UA113875C2 (uk) 2017-03-27
AU2013254849B2 (en) 2016-05-26
US20150087683A1 (en) 2015-03-26
BR112014026706A2 (pt) 2017-06-27
HK1201726A1 (en) 2015-09-11
PH12014502400A1 (en) 2015-01-12
KR20150010943A (ko) 2015-01-29
CA2873751A1 (en) 2013-10-31
PE20142356A1 (es) 2015-01-30
EP2841053A1 (en) 2015-03-04
DOP2014000238A (es) 2014-12-15
IL235159A0 (en) 2014-12-31
WO2013160222A1 (en) 2013-10-31
UY34762A (es) 2013-11-29
JP2015514792A (ja) 2015-05-21
NZ628394A (en) 2016-02-26

Similar Documents

Publication Publication Date Title
CY1125772T1 (el) Μακροκυκλικες ενωσεις για τη θεραπευτικη αντιμετωπιση νοσων
CY1123810T1 (el) Τριφθορομεθυλ υποκατεστημενα πυραζολια ως αναστολεις καλλικρεϊνης στο ανθρωπινο πλασμα
CY1122730T1 (el) 1,2,4-τριαζολες ως διαμορφωτες πυρηνικης μεταφορας και χρησεις αυτων
SA518391624B1 (ar) Ror- منظمات جاما
CY1119727T1 (el) Ενωσεις και συνθεσεις για τη θεραπεια παρασιτικων νοσων
EA201892395A1 (ru) Лекарственные составы ингибитора lsd1
WO2015106128A3 (en) Rnai agents modified at the 4'-c-position
UY35273A (es) Tiadiazol, análogos del mismo, y métodos para el tratamiento de condiciones relacionadas con defici encia de smn
EA201592256A1 (ru) Производные имидазопирролидинона и их применение при лечении заболеваний
MX382671B (es) Compuestos para usarse en el tratamiento o mejoramiento de la enfermedad de huntington
BR112018010650A8 (pt) pró-fármacos de um inibidor de jak composto para o tratamento da doença inflamatória gastrointestinal
CY1119227T1 (el) Παραγωγα πυριδινης ως ηπιοι αναστολεις της rock
EA201691058A1 (ru) Производные пирролопирролона и их применение для лечения заболеваний
MX2020004283A (es) Derivados de piridincarbonilo y usos terapéuticos de los mismos como inhibidores de trpc6.
EA201592254A1 (ru) Производные пиразолопирролидин-4-она и их применение при лечении заболевания
EA201592255A1 (ru) Производные пиразолопирролидин-4-она в качестве ингибиторов вет и их применение при лечении заболевания
CY1118947T1 (el) Ασυμμετρες ουριες και ιατρικες χρησεις αυτων
MX385762B (es) Métodos para el control transcripcional objetivo en regiones del super mejorador.
EA201692481A1 (ru) Комбинация, содержащая глюкокортикоид и edo-s101
MX2018003930A (es) Inhibidores de calicreína plasmática humana.
EA201692402A1 (ru) Лекарственные формы для местного применения и их использование
NI201600091A (es) UREAS ASIMÉTRICAS p-SUSTITUIDAS Y USOS MÉDICOS DE LAS MISMAS
JOP20190053A1 (ar) مركبات أزا إندازول للاستخدام في إصابات الأوتار و/ أو الرباط
MX389330B (es) Metodo de tratamiento de afecciones relacionadas con el receptor pgi2.
JOP20190086A1 (ar) مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب